Retatrutide

Peak Burn

The fat loss protocol that changes the conversation.

$299 AUD · $9.97/day · 30-day supply

Lyophilised powder vial · Subcutaneous injection · Self-administered

30-day full refund if you don't notice a difference. No return required.

24.2%
Mean body weight reduction at 48 weeks
NEJM Phase II · 2023
Australian Compounded
4.9 · 847 Reviews
30-Day Guarantee
Express Delivery AU-Wide

Mechanism

How Retatrutide Works.

Triple-receptor agonism. Three pathways, one compound — none previously combined at this potency.

Step 01

GLP-1 Agonism

Appetite suppression at source

Glucagon-like peptide-1 receptors in the hypothalamus regulate hunger signals. Retatrutide activates them directly — food stops being an obsession, not because of willpower but because the hypothalamic signal is turned down. This is the same pathway as Semaglutide, but it's only one of three here.

Step 02

GIP Agonism

Fat cell conversion

Glucose-dependent insulinotropic polypeptide receptors in adipose tissue. GIP agonism shifts fat cells from storage mode to release mode — a simultaneous metabolic gate not present in single-receptor compounds. Clinical data shows GIP addition amplifies the GLP-1 effect by approximately 30-40%.

Step 03

Glucagon Agonism

Direct fat oxidation

The third receptor — glucagon — directly promotes hepatic fat oxidation and increases thermogenesis. This is the mechanism that separates Retatrutide from every prior compound in its class. Glucagon acts on fat while GLP-1 and GIP act on appetite and insulin — the three pathways operate concurrently.

Clinical Data

The Research.

We cite the compound, not the product. These are Retatrutide's published results — the same compound in Peak Burn.

Jastreboff et al. · NEJM 2023 · Phase II Randomised Trial

"At the highest dose tested (12mg, once weekly), Retatrutide achieved a mean body weight reduction of 24.2% over 48 weeks. This represents the largest weight reduction observed in any pharmacological trial to date — greater than Semaglutide at equivalent duration."

N=338 participants. Primary endpoint met. Side-effect profile consistent with GLP-1 class: mild nausea, manageable with dose titration.

Compound Mechanism · Triple-Receptor Action · Published Data

"GLP-1 alone (Semaglutide/Ozempic) achieves approximately 15% body weight reduction at 68 weeks. The addition of GIP and glucagon agonism in Retatrutide approximately doubles the metabolic effect while compressing the timeline from 68 to 48 weeks."

Retatrutide is the first triple-receptor agonist to complete Phase II trials. Phase III is underway as of 2024.

Protocol

The Schedule.

The clinical trial used a progressive titration protocol. Below is the dosing schedule used in the NEJM Phase II trial.

Phase Duration Dose Frequency Expected Effect
Titration Weeks 1–4 2mg Once weekly Receptor priming — appetite changes begin
Escalation Weeks 5–8 4mg Once weekly Measurable body composition shift
Full Protocol Weeks 9–24 8mg Once weekly Sustained fat oxidation
Maintenance Weeks 25+ 8–12mg Once weekly Weight stabilisation

Dosing schedule based on the NEJM Phase II trial protocol. Not medical advice. Consult a healthcare professional before use.

Customer Results

They Ran It.

10,347 Australians
4.9★ · 847 reviews
1-in-3 re-order within 60 days
★★★★★
Down 11.4kg in 8 weeks on Burn. I’ve been on Ozempic before — the hunger suppression on Retatrutide is categorically different. No side effects. Just… food stopped being an obsession.
James T. — Sydney, 42, runs his own business — Burn (Retatrutide)
★★★★★
16kg in 12 weeks. My GP asked what I was doing. I told him. He asked me for the compound name and wrote it down. He’s looking into it for his other patients.
Karen M. — Brisbane, 47, nurse — Burn (Retatrutide)
★★★★★
I’d tried everything. Ozempic twice, a caloric deficit for 9 months, two personal trainers. Nothing moved the needle like this. Week 3 I knew something different was happening. 8 weeks in I’m down 9.2kg and I’m not hungry. I’m just not hungry.
Paul D. — Melbourne, 39, accountant — Burn (Retatrutide)

FAQ

Common Questions.

No. Ozempic and Wegovy contain Semaglutide — a GLP-1 single-receptor agonist. Retatrutide targets three receptors simultaneously: GLP-1, GIP, and glucagon. The Phase II trial data shows approximately double the body weight reduction of Semaglutide at equivalent duration. They operate on similar pathways, but Retatrutide is a fundamentally different compound in terms of mechanism and outcome.
Trial participants reported appetite changes within the first 2 weeks at the titration dose. Measurable body composition changes (scale weight, clothing fit) were typically reported at 4–6 weeks. The full effect compounded through weeks 8–24. Individual results vary based on starting weight, diet, and activity level.
The most common stack is Burn + Wolverine + Rewind. Wolverine (BPC-157 + TB-500) supports connective tissue during rapid body composition change — relevant if you're adding exercise. Rewind (NAD+) supports cellular energy systems during increased fat oxidation. There are no known compound interactions between Retatrutide and BPC-157, NAD+, or MOTS-C.
The NEJM Phase II trial reported mild-to-moderate nausea and reduced appetite in a subset of participants, consistent with the GLP-1 drug class. These were most common at the titration phase (weeks 1–4) and typically resolved as the body adapted. No serious adverse events were attributed to Retatrutide in the Phase II data. If you have a history of thyroid cancer, MEN2, or pancreatitis, consult a doctor before use — this is a compound-class caution across all GLP-1 agonists.
30-day full refund, no return required. We expect you to notice a difference — reduced appetite within 2 weeks, body composition change within 6. If you don't, we return your $299 in full. That reflects our confidence in what we compound, not a marketing softener.
Ships as lyophilised powder in a sterile vial. Reconstitute with bacteriostatic water using a fresh syringe and needle. Administer via subcutaneous injection — the lower abdomen or flank is the most common site. Rotate injection sites session to session. Ships stable at ambient temperature; refrigerate on arrival and use reconstituted solution within 21–28 days.
Standard workplace and roadside drug screens test for recreational substances and common medications — peptides will not appear on these screens. If you compete in a WADA-sanctioned sport, verify the current prohibited list at wada-ama.org before use, as regulations update annually. We recommend confirming with your sport's governing body before any sanctioned competition.